Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Zootaxa ; 3750: 89-94, 2013 Dec 17.
Artigo em Inglês | MEDLINE | ID: mdl-25113680

RESUMO

Thoracochirus yunxianius sp. nov. is described from Yunnan, China. Color images of the habitus and aedeagus of the new species are included. A key to the genus Thoracochirus of mainland China species is provided.


Assuntos
Besouros/classificação , Distribuição Animal , Estruturas Animais , Animais , China , Besouros/anatomia & histologia , Ecossistema , Feminino , Masculino
2.
Chin Med J (Engl) ; 125(10): 1690-4, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22800885

RESUMO

BACKGROUND: Dipeptidyl peptidase-IV (DPP-4) inhibitors are now used to improve postprandial glycemic control in type 2 diabetes. However, their effects on hepatic glucose production (HGP) in obesity are not clear. This study was designed to test the hypothesis that gluconeogenesis and HGP can be modulated by DPP-4 inhibitors in obesity. METHODS: Sprague Dawley male rats were divided into four groups, each on a different diet: general rat chow, n = 10 (G); G + sitagliptin, n = 10; high fat chow (obesity), n = 10 (55% fat calories, HFO); HFO + sitagliptin, n = 10. After 10 weeks, the rats were fasted overnight and glucose metabolism was determined using 3-(3)H-glucose and (14)C-glycerol as tracers. RESULTS: Glycerol rate of appearance (P < 0.00001), plasma glycerol (P < 0.05) and free fatty acid (FFA) (P < 0.05) concentrations, and HGP (P < 0.05) were decreased in HFO + sitagliptin group compared with HFO group, but there was no significant difference between G and G + sitagliptin groups (P > 0.05). Gluconeogenesis in HFO group was five times of that in G rats (P < 0.01), but was significantly declined in HFO + sitagliptin group (P < 0.0001). CONCLUSIONS: Gluconeogenesis and HGP were inhibited by sitagliptin in high fat-induced obese rats due to decreased glycerol availability, which was a result of reduced glycerol release from adipose tissues. The finding suggests that sitagliptin is potentially useful for controlling fasting glucose in obesity, thereby delaying or preventing the development of diabetes.


Assuntos
Inibidores da Dipeptidil Peptidase IV/uso terapêutico , Glucose/metabolismo , Fígado/efeitos dos fármacos , Fígado/metabolismo , Obesidade/tratamento farmacológico , Obesidade/metabolismo , Pirazinas/uso terapêutico , Triazóis/uso terapêutico , Animais , Masculino , Ratos , Ratos Sprague-Dawley , Fosfato de Sitagliptina
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa